BridgeBio late-stage genetic disease therapies set for US launches by 2027
BridgeBio says BBP-418, encaleret, and infigratinib are set for US launches by 2027, supporting a pipeline that includes three approved medicines and late-stage candidates targeting rare genetic diseases.